Advertisement
Screener

MOONLAKE IMMUNOTHERAPEUTICS (MLTX) Stock Redeemed or Called During Period, Value

2.8 / 5 stars · 68/120 Roast Me

MOONLAKE IMMUNOTHERAPEUTICS Stock Redeemed or Called During Period, Value

MOONLAKE IMMUNOTHERAPEUTICS (MLTX) reported Stock Redeemed or Called During Period, Value of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2026-02-25.

Financial Statements › Shareholders' Equity

us-gaap:StockRedeemedOrCalledDuringPeriodValue · last filed 2026-02-25

  • MOONLAKE IMMUNOTHERAPEUTICS stock redeemed or called during period, value for the quarter ending 2024-03-31 was $0.00.
  • MOONLAKE IMMUNOTHERAPEUTICS stock redeemed or called during period, value for the quarter ending 2021-06-30 was $152.33K.
  • MOONLAKE IMMUNOTHERAPEUTICS stock redeemed or called during period, value for the quarter ending 2021-03-31 was $76.29K.
  • MOONLAKE IMMUNOTHERAPEUTICS stock redeemed or called during period, value for fiscal 2024 was $0.00.
Period endStock Redeemed or Called During Period, Value 3 monthStock Redeemed or Called During Period, Value 5 monthStock Redeemed or Called During Period, Value 6 monthStock Redeemed or Called During Period, Value 12 month
2024-12-31$0.00
10-K · filed 2026-02-25
2024-03-31$0.00
10-Q · filed 2025-11-05
2021-06-30$152.33K
10-Q · filed 2021-08-16
$228.62K
derived: sum of 2 quarters · filed 2021-08-16
2021-03-31$76.29K
10-Q · filed 2021-08-16
2020-12-31$6.75M
10-K/A · filed 2021-12-14

Similar stocks

Stock NameCountryMarket CapPE Ratio
Pacira BioSciences, Inc. (PCRX)United States$1.020B69.03
Savara Inc (SVRA)United States$1.044B-9.10
Janux Therapeutics, Inc. (JANX)United States$1.019B-9.15
MANNKIND CORP (MNKD)United States$1.058B-30.41
Alto Neuroscience, Inc. (ANRO)United States$1.065B-11.02
Corvus Pharmaceuticals, Inc. (CRVS)United States$0.994B-23.25
Kura Oncology, Inc. (KURA)United States$0.967B-3.29
Arbutus Biopharma Corp (ABUS)$0.965B6.19
Amphastar Pharmaceuticals, Inc. (AMPH)United States$1.116B10.93
Jade Biosciences, Inc. (JBIO)United States$0.936B-9.21